Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.

Genta, Sofia; Martorana, Federica; Stathis, Anastasios; Colombo, Ilaria

Genta, Sofia; Martorana, Federica; Stathis, Anastasios; Colombo, Ilaria.

Afiliação

Genta S; New Drugs Development Unit, Service of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Martorana F; New Drugs Development Unit, Service of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Stathis A; New Drugs Development Unit, Service of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.
Colombo I; New Drugs Development Unit, Service of Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland. Electronic address: ilaria.colombo@eoc.ch.

Crit Rev Oncol Hematol ; 168: 103539, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34800653

Assuntos

Antineoplásicos; Neoplasias; Antineoplásicos/uso terapêutico; Dano ao DNA; Reparo do DNA; Humanos; Neoplasias/tratamento farmacológico; Neoplasias/genética; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico; Poli(ADP-Ribose) Polimerases

Palavras-chave

Cell-cycle checkpoint inhibitors; DNA damage response; Homologous recombination; PARP inhibitors; PARP inhibitors resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article